Journal: Brain Sciences

Article Title: Systemic Dental Pulp Stem Cell Secretome Therapy in a Mouse Model of Amyotrophic Lateral Sclerosis

doi: 10.3390/brainsci9070165

Figure Lengend Snippet: Late pre-symptomatic DPSC-CM treatment in mSOD1 G93A mice significantly attenuated ventral horn MN loss. Daily systemic DPSC-CM treatment from PD70–91 significantly increased MN survival in the mSOD1 G93A mouse lumbar spinal cord ventral horn compared to vehicle treatment, as measured by NeuN+ cells (green) in the ventral horn. Motor neurons in both Vehicle (Veh) and DPSC-CM treated mSOD1 G93A mice were significantly less than those in wild-type (WT) mouse lumbar spinal cord. Blue labeling indicates cell nuclei. Data represent mean +/− SEM. Data analyzed via one-way ANOVA. (WT, n = 3; mSOD1 G93A , n = 5–6). *, p < 0.05; ***, p < 0.001. Scale bar = 150 μm.

Article Snippet: In brief, 12–15 sections per mouse across 400 μm of the lumbar spinal cord were selected and incubated with primary rabbit monoclonal anti-NeuN antibody (1:500, Cat. #12943, Cell Signaling, Inc., Beverly, MA, USA) to label neurons.

Techniques: Labeling

Journal: The Cochrane Database of Systematic Reviews

Article Title: Ciclesonide versus other inhaled corticosteroids for chronic asthma in children

doi: 10.1002/14651858.CD010352

Figure Lengend Snippet: Characteristics of the interventions

Article Snippet: Budesonide 400 μg once daily Delivery: ciclesonide: hydro‐fluoroalkane metered dose inhaler (HFA‐MDI) (+ AeroChamber®); budesonide: Pulmicort Turbohaler® Inhalation technique: not described Treatment period: 12 weeks Allowed co‐medication: none % on ICS: not reported Outcomes FEV 1, peak expiratory flow, asthma symptoms, rescue medication, bone growth, 24‐hour urinary cortisol, adverse events Notes Analysis of co‐variance included baseline value at randomisations visit and age as co‐variates Funding: this study was funded and sponsored by ALTANA Pharma.

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Ciclesonide versus other inhaled corticosteroids for chronic asthma in children

doi: 10.1002/14651858.CD010352

Figure Lengend Snippet: Effect of the intervention: ciclesonide versus budesonide

Article Snippet: Budesonide 400 μg once daily Delivery: ciclesonide: hydro‐fluoroalkane metered dose inhaler (HFA‐MDI) (+ AeroChamber®); budesonide: Pulmicort Turbohaler® Inhalation technique: not described Treatment period: 12 weeks Allowed co‐medication: none % on ICS: not reported Outcomes FEV 1, peak expiratory flow, asthma symptoms, rescue medication, bone growth, 24‐hour urinary cortisol, adverse events Notes Analysis of co‐variance included baseline value at randomisations visit and age as co‐variates Funding: this study was funded and sponsored by ALTANA Pharma.

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Ciclesonide versus other inhaled corticosteroids for chronic asthma in children

doi: 10.1002/14651858.CD010352

Figure Lengend Snippet: Ciclesonide versus budesonide (dose ratio 1:2) for chronic asthma in children

Article Snippet: Budesonide 400 μg once daily Delivery: ciclesonide: hydro‐fluoroalkane metered dose inhaler (HFA‐MDI) (+ AeroChamber®); budesonide: Pulmicort Turbohaler® Inhalation technique: not described Treatment period: 12 weeks Allowed co‐medication: none % on ICS: not reported Outcomes FEV 1, peak expiratory flow, asthma symptoms, rescue medication, bone growth, 24‐hour urinary cortisol, adverse events Notes Analysis of co‐variance included baseline value at randomisations visit and age as co‐variates Funding: this study was funded and sponsored by ALTANA Pharma.

Techniques: Comparison, Control

Journal: The Cochrane Database of Systematic Reviews

Article Title: Ciclesonide versus other inhaled corticosteroids for chronic asthma in children

doi: 10.1002/14651858.CD010352

Figure Lengend Snippet: Comparison 1 Ciclesonide versus budesonide (dose ratio 1:2), Outcome 1 Patients with exacerbations.

Article Snippet: Budesonide 400 μg once daily Delivery: ciclesonide: hydro‐fluoroalkane metered dose inhaler (HFA‐MDI) (+ AeroChamber®); budesonide: Pulmicort Turbohaler® Inhalation technique: not described Treatment period: 12 weeks Allowed co‐medication: none % on ICS: not reported Outcomes FEV 1, peak expiratory flow, asthma symptoms, rescue medication, bone growth, 24‐hour urinary cortisol, adverse events Notes Analysis of co‐variance included baseline value at randomisations visit and age as co‐variates Funding: this study was funded and sponsored by ALTANA Pharma.

Techniques: Comparison

Journal: The Cochrane Database of Systematic Reviews

Article Title: Ciclesonide versus other inhaled corticosteroids for chronic asthma in children

doi: 10.1002/14651858.CD010352

Figure Lengend Snippet: Comparison 1 Ciclesonide versus budesonide (dose ratio 1:2), Outcome 2 Quality of life PAQLQ (S).

Article Snippet: Budesonide 400 μg once daily Delivery: ciclesonide: hydro‐fluoroalkane metered dose inhaler (HFA‐MDI) (+ AeroChamber®); budesonide: Pulmicort Turbohaler® Inhalation technique: not described Treatment period: 12 weeks Allowed co‐medication: none % on ICS: not reported Outcomes FEV 1, peak expiratory flow, asthma symptoms, rescue medication, bone growth, 24‐hour urinary cortisol, adverse events Notes Analysis of co‐variance included baseline value at randomisations visit and age as co‐variates Funding: this study was funded and sponsored by ALTANA Pharma.

Techniques: Comparison

Journal: The Cochrane Database of Systematic Reviews

Article Title: Ciclesonide versus other inhaled corticosteroids for chronic asthma in children

doi: 10.1002/14651858.CD010352

Figure Lengend Snippet: Comparison 1 Ciclesonide versus budesonide (dose ratio 1:2), Outcome 3 FEV1 least square means (L).

Article Snippet: Budesonide 400 μg once daily Delivery: ciclesonide: hydro‐fluoroalkane metered dose inhaler (HFA‐MDI) (+ AeroChamber®); budesonide: Pulmicort Turbohaler® Inhalation technique: not described Treatment period: 12 weeks Allowed co‐medication: none % on ICS: not reported Outcomes FEV 1, peak expiratory flow, asthma symptoms, rescue medication, bone growth, 24‐hour urinary cortisol, adverse events Notes Analysis of co‐variance included baseline value at randomisations visit and age as co‐variates Funding: this study was funded and sponsored by ALTANA Pharma.

Techniques: Comparison

Journal: The Cochrane Database of Systematic Reviews

Article Title: Ciclesonide versus other inhaled corticosteroids for chronic asthma in children

doi: 10.1002/14651858.CD010352

Figure Lengend Snippet: Effects of the intervention: ciclesonide versus fluticasone

Article Snippet: Budesonide 400 μg once daily Delivery: ciclesonide: hydro‐fluoroalkane metered dose inhaler (HFA‐MDI) (+ AeroChamber®); budesonide: Pulmicort Turbohaler® Inhalation technique: not described Treatment period: 12 weeks Allowed co‐medication: none % on ICS: not reported Outcomes FEV 1, peak expiratory flow, asthma symptoms, rescue medication, bone growth, 24‐hour urinary cortisol, adverse events Notes Analysis of co‐variance included baseline value at randomisations visit and age as co‐variates Funding: this study was funded and sponsored by ALTANA Pharma.

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Ciclesonide versus other inhaled corticosteroids for chronic asthma in children

doi: 10.1002/14651858.CD010352

Figure Lengend Snippet: Comparison 2 Ciclesonide versus fluticasone, Outcome 1 Patients with exacerbations.

Article Snippet: Budesonide 400 μg once daily Delivery: ciclesonide: hydro‐fluoroalkane metered dose inhaler (HFA‐MDI) (+ AeroChamber®); budesonide: Pulmicort Turbohaler® Inhalation technique: not described Treatment period: 12 weeks Allowed co‐medication: none % on ICS: not reported Outcomes FEV 1, peak expiratory flow, asthma symptoms, rescue medication, bone growth, 24‐hour urinary cortisol, adverse events Notes Analysis of co‐variance included baseline value at randomisations visit and age as co‐variates Funding: this study was funded and sponsored by ALTANA Pharma.

Techniques: Comparison

Journal: The Cochrane Database of Systematic Reviews

Article Title: Ciclesonide versus other inhaled corticosteroids for chronic asthma in children

doi: 10.1002/14651858.CD010352

Figure Lengend Snippet: Comparison 2 Ciclesonide versus fluticasone, Outcome 2 Adverse events: number of patients with adverse events.

Article Snippet: Budesonide 400 μg once daily Delivery: ciclesonide: hydro‐fluoroalkane metered dose inhaler (HFA‐MDI) (+ AeroChamber®); budesonide: Pulmicort Turbohaler® Inhalation technique: not described Treatment period: 12 weeks Allowed co‐medication: none % on ICS: not reported Outcomes FEV 1, peak expiratory flow, asthma symptoms, rescue medication, bone growth, 24‐hour urinary cortisol, adverse events Notes Analysis of co‐variance included baseline value at randomisations visit and age as co‐variates Funding: this study was funded and sponsored by ALTANA Pharma.

Techniques: Comparison

Journal: The Cochrane Database of Systematic Reviews

Article Title: Ciclesonide versus other inhaled corticosteroids for chronic asthma in children

doi: 10.1002/14651858.CD010352

Figure Lengend Snippet: Comparison 2 Ciclesonide versus fluticasone, Outcome 3 Adverse events: 24‐ hour urine free cortisol adjusted for creatinine (nmol/mmol).

Article Snippet: Budesonide 400 μg once daily Delivery: ciclesonide: hydro‐fluoroalkane metered dose inhaler (HFA‐MDI) (+ AeroChamber®); budesonide: Pulmicort Turbohaler® Inhalation technique: not described Treatment period: 12 weeks Allowed co‐medication: none % on ICS: not reported Outcomes FEV 1, peak expiratory flow, asthma symptoms, rescue medication, bone growth, 24‐hour urinary cortisol, adverse events Notes Analysis of co‐variance included baseline value at randomisations visit and age as co‐variates Funding: this study was funded and sponsored by ALTANA Pharma.

Techniques: Comparison

Journal: The Cochrane Database of Systematic Reviews

Article Title: Ciclesonide versus other inhaled corticosteroids for chronic asthma in children

doi: 10.1002/14651858.CD010352

Figure Lengend Snippet: Comparison 2 Ciclesonide versus fluticasone, Outcome 4 Generic FEV1 least square mean (L).

Article Snippet: Budesonide 400 μg once daily Delivery: ciclesonide: hydro‐fluoroalkane metered dose inhaler (HFA‐MDI) (+ AeroChamber®); budesonide: Pulmicort Turbohaler® Inhalation technique: not described Treatment period: 12 weeks Allowed co‐medication: none % on ICS: not reported Outcomes FEV 1, peak expiratory flow, asthma symptoms, rescue medication, bone growth, 24‐hour urinary cortisol, adverse events Notes Analysis of co‐variance included baseline value at randomisations visit and age as co‐variates Funding: this study was funded and sponsored by ALTANA Pharma.

Techniques: Comparison

Journal: The Cochrane Database of Systematic Reviews

Article Title: Ciclesonide versus other inhaled corticosteroids for chronic asthma in children

doi: 10.1002/14651858.CD010352

Figure Lengend Snippet: Ciclesonide versus fluticasone (dose ratio 1:1) for chronic asthma in children

Article Snippet: Budesonide 400 μg once daily Delivery: ciclesonide: hydro‐fluoroalkane metered dose inhaler (HFA‐MDI) (+ AeroChamber®); budesonide: Pulmicort Turbohaler® Inhalation technique: not described Treatment period: 12 weeks Allowed co‐medication: none % on ICS: not reported Outcomes FEV 1, peak expiratory flow, asthma symptoms, rescue medication, bone growth, 24‐hour urinary cortisol, adverse events Notes Analysis of co‐variance included baseline value at randomisations visit and age as co‐variates Funding: this study was funded and sponsored by ALTANA Pharma.

Techniques: Comparison, Control

Journal: The Cochrane Database of Systematic Reviews

Article Title: Ciclesonide versus other inhaled corticosteroids for chronic asthma in children

doi: 10.1002/14651858.CD010352

Figure Lengend Snippet: Ciclesonide versus fluticasone (dose ratio 1:2) for chronic asthma in children

Article Snippet: Budesonide 400 μg once daily Delivery: ciclesonide: hydro‐fluoroalkane metered dose inhaler (HFA‐MDI) (+ AeroChamber®); budesonide: Pulmicort Turbohaler® Inhalation technique: not described Treatment period: 12 weeks Allowed co‐medication: none % on ICS: not reported Outcomes FEV 1, peak expiratory flow, asthma symptoms, rescue medication, bone growth, 24‐hour urinary cortisol, adverse events Notes Analysis of co‐variance included baseline value at randomisations visit and age as co‐variates Funding: this study was funded and sponsored by ALTANA Pharma.

Techniques: Comparison, Control

Journal: The Cochrane Database of Systematic Reviews

Article Title: Ciclesonide versus other inhaled corticosteroids for chronic asthma in children

doi: 10.1002/14651858.CD010352

Figure Lengend Snippet: Ciclesonide versus budesonide (dose ratio 1:2)

Article Snippet: Budesonide 400 μg once daily Delivery: ciclesonide: hydro‐fluoroalkane metered dose inhaler (HFA‐MDI) (+ AeroChamber®); budesonide: Pulmicort Turbohaler® Inhalation technique: not described Treatment period: 12 weeks Allowed co‐medication: none % on ICS: not reported Outcomes FEV 1, peak expiratory flow, asthma symptoms, rescue medication, bone growth, 24‐hour urinary cortisol, adverse events Notes Analysis of co‐variance included baseline value at randomisations visit and age as co‐variates Funding: this study was funded and sponsored by ALTANA Pharma.

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Ciclesonide versus other inhaled corticosteroids for chronic asthma in children

doi: 10.1002/14651858.CD010352

Figure Lengend Snippet: Ciclesonide versus fluticasone

Article Snippet: Budesonide 400 μg once daily Delivery: ciclesonide: hydro‐fluoroalkane metered dose inhaler (HFA‐MDI) (+ AeroChamber®); budesonide: Pulmicort Turbohaler® Inhalation technique: not described Treatment period: 12 weeks Allowed co‐medication: none % on ICS: not reported Outcomes FEV 1, peak expiratory flow, asthma symptoms, rescue medication, bone growth, 24‐hour urinary cortisol, adverse events Notes Analysis of co‐variance included baseline value at randomisations visit and age as co‐variates Funding: this study was funded and sponsored by ALTANA Pharma.

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Ciclesonide versus other inhaled corticosteroids for chronic asthma in children

doi: 10.1002/14651858.CD010352

Figure Lengend Snippet: Hiremath 2006

Article Snippet: Budesonide 400 μg once daily Delivery: ciclesonide: hydro‐fluoroalkane metered dose inhaler (HFA‐MDI) (+ AeroChamber®); budesonide: Pulmicort Turbohaler® Inhalation technique: not described Treatment period: 12 weeks Allowed co‐medication: none % on ICS: not reported Outcomes FEV 1, peak expiratory flow, asthma symptoms, rescue medication, bone growth, 24‐hour urinary cortisol, adverse events Notes Analysis of co‐variance included baseline value at randomisations visit and age as co‐variates Funding: this study was funded and sponsored by ALTANA Pharma.

Techniques: Medications, Sequencing, Selection

Journal: The Cochrane Database of Systematic Reviews

Article Title: Ciclesonide versus other inhaled corticosteroids for chronic asthma in children

doi: 10.1002/14651858.CD010352

Figure Lengend Snippet: Paunovic 2010

Article Snippet: Budesonide 400 μg once daily Delivery: ciclesonide: hydro‐fluoroalkane metered dose inhaler (HFA‐MDI) (+ AeroChamber®); budesonide: Pulmicort Turbohaler® Inhalation technique: not described Treatment period: 12 weeks Allowed co‐medication: none % on ICS: not reported Outcomes FEV 1, peak expiratory flow, asthma symptoms, rescue medication, bone growth, 24‐hour urinary cortisol, adverse events Notes Analysis of co‐variance included baseline value at randomisations visit and age as co‐variates Funding: this study was funded and sponsored by ALTANA Pharma.

Techniques: Sequencing, Selection

Journal: The Cochrane Database of Systematic Reviews

Article Title: Ciclesonide versus other inhaled corticosteroids for chronic asthma in children

doi: 10.1002/14651858.CD010352

Figure Lengend Snippet: Pedersen 2006

Article Snippet: Budesonide 400 μg once daily Delivery: ciclesonide: hydro‐fluoroalkane metered dose inhaler (HFA‐MDI) (+ AeroChamber®); budesonide: Pulmicort Turbohaler® Inhalation technique: not described Treatment period: 12 weeks Allowed co‐medication: none % on ICS: not reported Outcomes FEV 1, peak expiratory flow, asthma symptoms, rescue medication, bone growth, 24‐hour urinary cortisol, adverse events Notes Analysis of co‐variance included baseline value at randomisations visit and age as co‐variates Funding: this study was funded and sponsored by ALTANA Pharma.

Techniques: Sequencing, Selection

Journal: The Cochrane Database of Systematic Reviews

Article Title: Ciclesonide versus other inhaled corticosteroids for chronic asthma in children

doi: 10.1002/14651858.CD010352

Figure Lengend Snippet: Vermeulen 2007

Article Snippet: Budesonide 400 μg once daily Delivery: ciclesonide: hydro‐fluoroalkane metered dose inhaler (HFA‐MDI) (+ AeroChamber®); budesonide: Pulmicort Turbohaler® Inhalation technique: not described Treatment period: 12 weeks Allowed co‐medication: none % on ICS: not reported Outcomes FEV 1, peak expiratory flow, asthma symptoms, rescue medication, bone growth, 24‐hour urinary cortisol, adverse events Notes Analysis of co‐variance included baseline value at randomisations visit and age as co‐variates Funding: this study was funded and sponsored by ALTANA Pharma.

Techniques: Sequencing, Selection, Generated

Journal: The Cochrane Database of Systematic Reviews

Article Title: Ciclesonide versus other inhaled corticosteroids for chronic asthma in children

doi: 10.1002/14651858.CD010352

Figure Lengend Snippet: von Berg 2007

Article Snippet: Budesonide 400 μg once daily Delivery: ciclesonide: hydro‐fluoroalkane metered dose inhaler (HFA‐MDI) (+ AeroChamber®); budesonide: Pulmicort Turbohaler® Inhalation technique: not described Treatment period: 12 weeks Allowed co‐medication: none % on ICS: not reported Outcomes FEV 1, peak expiratory flow, asthma symptoms, rescue medication, bone growth, 24‐hour urinary cortisol, adverse events Notes Analysis of co‐variance included baseline value at randomisations visit and age as co‐variates Funding: this study was funded and sponsored by ALTANA Pharma.

Techniques: Biomarker Discovery, Sequencing, Selection

Journal: The Cochrane Database of Systematic Reviews

Article Title: Ciclesonide versus other inhaled corticosteroids for chronic asthma in children

doi: 10.1002/14651858.CD010352

Figure Lengend Snippet: BY9010/M1‐205

Article Snippet: Budesonide 400 μg once daily Delivery: ciclesonide: hydro‐fluoroalkane metered dose inhaler (HFA‐MDI) (+ AeroChamber®); budesonide: Pulmicort Turbohaler® Inhalation technique: not described Treatment period: 12 weeks Allowed co‐medication: none % on ICS: not reported Outcomes FEV 1, peak expiratory flow, asthma symptoms, rescue medication, bone growth, 24‐hour urinary cortisol, adverse events Notes Analysis of co‐variance included baseline value at randomisations visit and age as co‐variates Funding: this study was funded and sponsored by ALTANA Pharma.

Techniques: Infection, Control

Journal: PLoS ONE

Article Title: CpG Methylation Analysis of HPV16 in Laser Capture Microdissected Archival Tissue and Whole Tissue Sections from High Grade Anal Squamous Intraepithelial Lesions: A Potential Disease Biomarker

doi: 10.1371/journal.pone.0160673

Figure Lengend Snippet: Schematic representation of the HPV16 URR including the 10 CpG sites studied and location of PCR primers.

Article Snippet: HPV16 positive cervical carcinoma cell lines CaSki (approximately 400 copies per cell of the HPV16 genome, ATCC CRL1550; American Type Culture Collection (ATCC), Manassas, VA, USA) and SiHa (1–2 copies of HPV16 per cell, ATCC HTB35; ATCC), previously characterised as having high and low CpG methylation levels respectively in the HPV16 URR [ ], were used as methylation controls and during standardization of PCRs and pyrosequencing assays.

Techniques:

Journal: PLoS ONE

Article Title: CpG Methylation Analysis of HPV16 in Laser Capture Microdissected Archival Tissue and Whole Tissue Sections from High Grade Anal Squamous Intraepithelial Lesions: A Potential Disease Biomarker

doi: 10.1371/journal.pone.0160673

Figure Lengend Snippet: Serial dilutions of SiHa were subjected to primary PCR using specific primers for (A) E2BS1 region and (B) E2BS2,3,4 region of HPV16 in triplicate reactions. The primary PCR reactions were then used as templates to conduct nested PCR.

Article Snippet: HPV16 positive cervical carcinoma cell lines CaSki (approximately 400 copies per cell of the HPV16 genome, ATCC CRL1550; American Type Culture Collection (ATCC), Manassas, VA, USA) and SiHa (1–2 copies of HPV16 per cell, ATCC HTB35; ATCC), previously characterised as having high and low CpG methylation levels respectively in the HPV16 URR [ ], were used as methylation controls and during standardization of PCRs and pyrosequencing assays.

Techniques: Nested PCR

Journal: PLoS ONE

Article Title: CpG Methylation Analysis of HPV16 in Laser Capture Microdissected Archival Tissue and Whole Tissue Sections from High Grade Anal Squamous Intraepithelial Lesions: A Potential Disease Biomarker

doi: 10.1371/journal.pone.0160673

Figure Lengend Snippet: Inter-assay reproducibility and intra-assay repeatability of methylation at 10 different CpG sites of HPV16 URR in CaSki and SiHa cells.

Article Snippet: HPV16 positive cervical carcinoma cell lines CaSki (approximately 400 copies per cell of the HPV16 genome, ATCC CRL1550; American Type Culture Collection (ATCC), Manassas, VA, USA) and SiHa (1–2 copies of HPV16 per cell, ATCC HTB35; ATCC), previously characterised as having high and low CpG methylation levels respectively in the HPV16 URR [ ], were used as methylation controls and during standardization of PCRs and pyrosequencing assays.

Techniques: Inter Assay, Intra Assay, Methylation

Journal: PLoS ONE

Article Title: CpG Methylation Analysis of HPV16 in Laser Capture Microdissected Archival Tissue and Whole Tissue Sections from High Grade Anal Squamous Intraepithelial Lesions: A Potential Disease Biomarker

doi: 10.1371/journal.pone.0160673

Figure Lengend Snippet: Representative pyrograms showing methylation levels at 10 CpG sites within the E2BS1, E2BS2,3,4 and Sp1 binding sites of HPV16 URR in SiHa and CaSki cells using nested amplified products.

Article Snippet: HPV16 positive cervical carcinoma cell lines CaSki (approximately 400 copies per cell of the HPV16 genome, ATCC CRL1550; American Type Culture Collection (ATCC), Manassas, VA, USA) and SiHa (1–2 copies of HPV16 per cell, ATCC HTB35; ATCC), previously characterised as having high and low CpG methylation levels respectively in the HPV16 URR [ ], were used as methylation controls and during standardization of PCRs and pyrosequencing assays.

Techniques: Methylation, Binding Assay, Amplification